webinar recording available - register to watch

Unlocking biotech’s potential: Strategies for navigating public and private market investments

As biotech activity begins to heat up, new transaction patterns are emerging and shaping how investments flow into the sector. Robust innovation and a recent burst of IPO activity is driving positive investor sentiment and supporting increased participation in both public and private markets.

But as we head into Q4, several factors will continue to shape the funding landscape, including subdued exit environment across M&A and equity markets, paired with uncertainty around the upcoming U.S. presidential election. However, biotech’s sharp focus on innovation and investors’ ability to adapt to market signals suggests a bright future lies ahead.

Join venture capital visionaries and fund founders Craig Gordon, MD, Founder, CEO, and CIO at GordonMD® Global Investments LP, Srini Akkaraju, MD, PhD, Founder & Managing Partner at Samsara BioCapital, and Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, for a discussion exploring how biotech investment opportunities are evolving across public and private markets, with insights into emerging modalities and key therapeutic areas.

watch now
watch the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Craig Gordon

Craig Gordon

Founder, CEO, and CIO, GordonMD® Global Investments LP

Prior to establishing GordonMD® Global Investments in 2021, Dr. Gordon worked at The Capital Group for 10+ years as an Equity Investment Analyst investing in and covering U.S. and Japanese biotechnology and pharmaceutical companies. In this capacity, he conducted research and built his own differentiated portfolio, taking into consideration numerous factors including but not limited to appropriate sizing, risk levels, and timing of milestones.

Dr. Gordon worked for the Cowen Group in New York as a Biotechnology Equity Research Analyst and Associate before joining Capital Group in 2010.

In addition to being a licensed rheumatologist, Dr. Gordon is an investment manager, who has personally managed on average $7 billion or more, and provided help in overseeing additional portfolios totaling billions more.

Srini Akkaraju

Srini Akkaraju

Founder & Managing Partner, Samsara BioCapital

Dr. Srinivas Akkaraju is the Founder and Managing General Partner at Samsara BioCapital. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture Partners. Previously, he served as a Managing Director at Panorama Capital, LLC, a private equity firm. Prior to co-founding Panorama Capital, Dr. Akkaraju was with J.P. Morgan Partners, which he joined in 2001 and of which he became a Partner in 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager.

Prior to joining Genentech, Dr. Akkaraju was a graduate student at Stanford University, where he received his MD and a PhD in Immunology. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University. Dr. Akkaraju serves as a director of Scholar Rock, Mineralys Therapeutics, Syros Pharmaceuticals, and several private biotechs. Previously, he served as a director on the boards of Seattle Genetics, Principia Biopharma, Chinook Therapeutics, Intercept Pharmaceuticals, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp., Amarin Corporation, Aravive, Inc., and Barrier Therapeutics.

Stefan Vitorovic

Stefan Vitorovic

Co-Founder and Managing Director, Vida Ventures

Prior to co-founding Vida Ventures, Stefan was an investment professional at Third Rock Ventures, an early-stage life sciences venture capital firm focused on company creation. Before Third Rock, Stefan was an investor at TPG Capital, where he focused on majority, control stakes in companies across the healthcare industry. Prior to TPG, Stefan was an investment banker at Credit Suisse’s healthcare banking group focused on M&A and equity financings.

Stefan received his B.S. with Honors in Biological Sciences at Stanford University where he was a Firestone Medalist. He completed his M.S. in Biology at Stanford, where he conducted biomedical research in the lab of Dr. Helen Blau at Stanford Medical School. Stefan later received his MBA from Harvard Business School. Stefan currently serves on the Board of Directors for Vigil Neuroscience (“VIGL”), Tectonic Therapeutic, Volastra Therapeutics, and Soufflé Therapeutics. He was previously a Board Director or Observer at Praxis Precision Medicines (“PRAX”), Kyverna Therapeutics (“KYTX”), Oyster Point Therapeutics (acq by Viatris), Dyne Therapeutics (“DYN”), Sutro Biopharma (“STRO”), Decibel Therapeutics (acq by Regeneron), Aptalis (acq by Forest Labs), and Biomet (acq by Zimmer). He lives in Boston and serves on the Board of the New England Venture Capital Association.

Noël Brown
moderator

Noël Brown

Managing Director and Head of U.S. Biotechnology Investment Banking, RBC Capital Markets

Noël Brown is the Managing Director and Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, responsible for leading the biotechnology franchise. He has over 20 years of investment banking experience. Noël graduated from the University of Western Ontario and received a law degree from the University of Ottawa and an MBA from the MIT Sloan School of Business.